Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewEticlopride hydrochloride
Description: D2 and D3 antagonist (D3 > D2)
Alternative Names: (-)-Eticlopride
Chemical Name: 3-Chloro-5-ethyl-N-[[(2S)-1-ethyl-2-pyrrolidinyl)methyl]-6-hydroxy-2-methoxy-benzamide hydrochloride
Purity: ≥99% (HPLC)
Biological Activity for Eticlopride hydrochloride
Eticlopride hydrochloride is a selective dopamine D2/D3 receptor antagonist (Ki values are 0.50 and 0.16 nM respectively). Antipsychotic.
Technical Data for Eticlopride hydrochloride
| M. Wt | 377.31 |
| Formula | C17H25ClN2O3.HCl |
| Storage | Desiccate at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 97612-24-3 |
| PubChem ID | 57266 |
| InChI Key | HFJFXXDHVWLIKX-YDALLXLXSA-N |
| Smiles | O=C(C2=C(OC)C(Cl)=CC(CC)=C2O)NC[C@@H]1CCCN1CC.Cl |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Eticlopride hydrochloride
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| water | 37.73 | 100 |
Preparing Stock Solutions for Eticlopride hydrochloride
The following data is based on the product molecular weight 377.31. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.65 mL | 13.25 mL | 26.5 mL |
| 5 mM | 0.53 mL | 2.65 mL | 5.3 mL |
| 10 mM | 0.27 mL | 1.33 mL | 2.65 mL |
| 50 mM | 0.05 mL | 0.27 mL | 0.53 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for Eticlopride hydrochloride
References for Eticlopride hydrochloride
References are publications that support the biological activity of the product.
Hall et al (1985) Some in vitro receptor binding properties of [3H]eticlopride, a novel substituted benzamide, selective for DA-D2 receptors in the rat brain. Eur.J.Pharmacol. 111 191 PMID: 4018125
Giuliani and Ferrari (1997) Involvement of DA receptors in the antipsychotic profile of (-) eticlopride. Physiol.Behav. 61 563 PMID: 9108576
Claytor et al (2006) The effects of eticlopride and the selective D3-antagonist PNU 99194-A on food- and cocaine-maintained responding in rhesus monkeys. Pharmacol.Biochem.Behav. 83 456 PMID: 16631246
If you know of a relevant reference for Eticlopride hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Eticlopride hydrochloride, Eticlopride hydrochloride supplier, Selective, antagonists, D3, D2, Dopamine, D2-like, Non-Selective, Receptors, dopaminergic, (-)-Eticlopride, Non-selective, 1847, Tocris Bioscience
7 Citations for Eticlopride hydrochloride
Citations are publications that use Tocris products. Selected citations for Eticlopride hydrochloride include:
Dorst et al (2020) Polysynaptic inhibition between striatal cholinergic interneurons shapes their network activity patterns in a dopamine-dependent manner. Nat Commun 11 5113 PMID: 33037215
Jensen (2015) Effects of DA D2-Like Receptor Antagonists on Light Responses of Ganglion Cells in Wild-Type and P23H Rat Retinas. PLoS One 10 e0146154 PMID: 26717015
Tønnesen et al (2011) Functional integration of grafted neural stem cell-derived DArgic neurons monitored by optogenetics in an in vitro Parkinson model. PLoS One 6 e17560 PMID: 21394212
Zhao et al (2014) Korean Red Ginseng attenuates anxiety-like behavior during ethanol withdrawal in rats. Neuropsychopharmacology 38 256 PMID: 25379005
Kramar et al (2014) DA in the dorsal hippocampus impairs the late consolidation of cocaine-associated memory. Int J Neuropsychopharmacol 39 1645 PMID: 24442095
Cassar et al (2015) A DA receptor contributes to paraquat-induced neurotoxicity in Drosophila. J Ginseng Res 24 197 PMID: 25158689
Burgess et al (2010) DArgic regulation of sleep and cataplexy in a murine model of narcolepsy. Sleep 33 1295 PMID: 21061851
Do you know of a great paper that uses Eticlopride hydrochloride from Tocris? Please let us know.
Reviews for Eticlopride hydrochloride
Average Rating: 5 (Based on 1 Review.)
Have you used Eticlopride hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Effects of eticlopride on cue-induced reinstatement of food seeking.
By
Kevin Ball on 01/22/2019
Assay Type: In Vivo
Species: Rat
At a dose that did not alter responding during food self-administration (6.0 micrograms/kg), systemic injections of eticlopride significantly increased responding during cue-induced reinstatement of food seeking tests.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.